Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DGT-SM-Cancer3
- Development stage
- Preclinical
- Lead developer
- dGenThera
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
DGT-SM-Cancer3 is an undisclosed small-molecule targeted radiotherapeutic currently in the discovery stage of development by dGenThera. The candidate is designed to target specific cellular transporters that are overexpressed in certain types of cancer, facilitating the delivery of a radioactive isotope directly to the tumor site. This approach aims to maximize therapeutic efficacy while minimizing off-target toxicity to healthy tissues. As of early 2024, the specific molecular target and the primary cancer indication (referred to as 'Cancer 3') have not been publicly disclosed by the developer.
- Other names
- dGenThera Cancer 3 small molecule radiotherapeutic
02
Targets
SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on DGT-SM-Cancer3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DGT-SM-Cancer3.